TEWKSBURY, Mass.--(BUSINESS WIRE)--Cambridge Heart, Inc. (OTCBB- CAMH - News), today announced that the Company has completed the development phase of its Microvolt T-wave Alternans (MTWA) OEM Module, and has submitted a 510(k) application for regulatory approval with the U.S. Food and Drug Administration (FDA). The module is the centerpiece of the Company’s new business model that involves partnering with leading stress test equipment manufacturers to broaden the distribution and use of MTWA technology.
